Funds and prices
Risks
All investments are subject to market fluctuations. Every fund has specific risks, which can significantly increase under unusual market conditions. Please consult your client advisor for more information on the investment risks of this product.
Features
Product category |
Equity
Europe |
Product domicile |
Switzerland
|
Portfolio management |
ÃÛ¶¹ÊÓƵ Asset Management Switzerland AG, Zurich
|
Fund management |
ÃÛ¶¹ÊÓƵ Fund Management (Switzerland) AG
|
Custodian bank |
ÃÛ¶¹ÊÓƵ Switzerland AG, Zurich
|
Day of inception |
October 26, 2020
|
Currency of account |
CHF
|
Close of financial year |
October 31
|
Issue / redemption |
daily
|
Distribution |
Reinvestment
|
Maturity |
Open end
|
Flat fee |
0.00%
|
Flat fee |
0.00% p.a.
|
Total expense ratio (TER) |
0.00% p.a.
|
Minimum investment |
n.a.
|
Reference Index / Benchmark |
MSCI United Kingdom (net div. reinv.) in CHF
|
Cut-Off Time |
15:00h (CET)
|
Securities no. |
56650910
|
ISIN |
CH0566509102
|
Bloomberg Ticker |
EQUPIIX SW
|
Telekurs Id |
IEUKPIX
|
Performance and Prices
Percentage growth
as of April 3, 2024
Cumulative
CHF(%) | EUR(%) | USD(%) | |
YTD | 10.66 | 4.94 | 2.81 |
1M | |||
3M | |||
6M | |||
1Y | |||
2Y | 3.69 | 10.12 | 13.98 |
3Y | 18.86 | 34.50 | 23.77 |
5Y | |||
ø p.a.5Y | 5.93 | 10.38 | 7.37 |
Current data
Net asset value | 03.04.2024 | CHF 1,488.29 |
High - last 12 months | 03.04.2024 | CHF 1,488.29 |
Low - last 12 months | 27.10.2023 | CHF 1,308.06 |
Assets of the unit class in mn | 03.04.2024 | CHF 422.97 |
Total product assets in mn | 03.04.2024 | CHF 1,237.87 |
Statistical data
Date
|
2 years
|
5 years
|
|
Total risk reference index / benchmark | 29.02.2024 | 14.34% | n.a. |
Sharpe Ratio | 29.02.2024 | -0.02 | n.a. |
Risk Free Rate | 31.03.2024 | 0.87% | -0.06% |
Structures
By the 10 largest positions (in %, as of February 29, 2024)
|
|
Shell PLC | 8.57 |
AstraZeneca PLC | 8.27 |
HSBC Holdings PLC | 6.30 |
Unilever PLC | 5.19 |
BP PLC | 4.21 |
GSK PLC | 3.66 |
Diageo PLC | 3.54 |
RELX PLC | 3.49 |
Rio Tinto PLC | 3.06 |
British American Tobacco PLC | 2.53 |
Fees
Distributions
No distributions. Continuous reinvestment of income.
Authorisations
Literature
Brochures
Agreement / Prospectus
Document type
|
Document Language
|
|||
Prospectus |
|
|
||
Past performance |
|
|
|
|
Previous performance scenario |
|
|
|
|
ASIP ESG Report |
|
|
|
Annual and semi-annual report (accounting on October 31)
Document type
|
Document Language
|
|
Annual report |
|
|